Abstract
Background
Cancer-associated hypercalcemia (CAH) is the most frequent metabolic disorder in cancer patients. We retrospectively reviewed the outcome and prognostic factors for patients with CAH being treated with standard intravenous disphosphonates.
Materials and methods
Two hundred sixty patients were reviewed. Overall survival and prognostic factors were analyzed. Relative risks (RR) for early death (within 60 days) were assessed (Fischer exact test and logistic regression model).
Results
Median survival was 64 days (range, 12–1,955+). Multivariate analysis identified the following factors as poor survival predictors: serum corrected calcium >2.83 mmol/l [hazard ratio (HR) = HR 2.21], albuminemia <35.5 (HR 2.41), squamous cell carcinoma (HR 2.64), bone metastasis (HR 1.44), and liver metastasis (HR 2..22). One hundred twenty-one patients died within 60 days. For those patients, the logistic regression model identified four independent predicting factors for early death: calcemia >2.83 mmol/l (RR 5.07), hypoalbuminemia (RR 7.42), liver metastasis (RR 4.34), and squamous cell carcinomas (RR 2.21).
Discussion
Despite intravenous diphosphonate, CAH is still associated with poor outcome. Simple bedside parameters may estimate the risk of early deaths.
Similar content being viewed by others
References
Besarb A, Caro JF (1978) Mechanisms of hypercalcemia in malignancy. Cancer 41:2276–2285
Brada M, Rowley M, Grant DJ, Ashley S, Powles TJ (1990) Hypercalcemia in patients with disseminated breast cancer. Acta Oncol 29:577–580
Body JJ, Borkowski A, Cleeren A et al (1986) Treatment of malignancy-associated hypercalcemia with intravenous aminohydroxypropylidene diphosphonate. J Clin Oncol 4:1177–1183
Nussbaum SR, Younger J, Vandepol CJ et al (1993) Single-dose intravenous therapy with pamidronate for the treatment of hypercalcemia of malignancy: comparison of 30-, 60-, and 90-mg dosages. Am J Med 95:297–304
Rogers MJ, Gordon S, Benford HL et al (2000) Cellular and molecular mechanisms of action of biphosphonates. Cancer 88:2961–2978
Major P, Lhortolary A, Hon J et al (2001) Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy a pooled analysis of two-randomized controlled clinical trials. J Clin Oncol 19:558–567
Monno S, Nagata A, Furuta S (1987) Hypercalcemia of cancer in the aerodigestive tract. J Clin Gastroenterol 9:78–82
Ralston SH, Gallacher SJ, Patel U, Campbell J, Boyle IT (1990) Cancer-associated hypercalcemia morbidity and mortality. Clinical experience in 126 treated patients. Ann Intern Med 112:499–504
Cvitkovic F, Armand JP, Tubiana-Hulin M, Rossi JF, Warrell RP Jr (2006) Randomized, double-blind, phase II trial of gallium nitrate compared with pamidronate for acute control of cancer-related hypercalcemia. Cancer J 12:47–53
Kristensen B, Ejlersten B, Mouridsen HT, Loft H (1998) Survival in breast cancer patients after the first episode of hypercalcemia. J Intern Med 244:189–198
Payne RB, Carver ME, Morgan DB (1979) Interpretation of serum total calcium effects of adjustment for albumin concentration on frequency of abnormal values and on detection of change in the individual. J Clin Pathol 32:56–60
Kaplan EL, Meier P (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457–481
Mantel N (1966) Estimation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50:163–170
Cox D (1972) Regression models and life tables (with discussion). J R Stat Soc B 34:187–220
Chasan SA, Pothel LR, Huben RP (1989) Management and prognostic significance of hypercalcemia in renal cell carcinomas. J Urology 33:167–170
Degardin M, N’Guyen M, Beaurin D et al (1995) Hypercalcémie et carcinomes épidermoides des voies aéro-digestives supérieures. Incidence et pronostic. Bull Cancer 82:975–980
Fahn HJ, Lee YH, Chen MT, Huang JK, Chen KK, Chang LS (1991) The incidence and prognostic significance of humoral hypercalcemia in renal cell carcinoma. J Urol 145:248–250
Penel N Berthon C, Everard F et al (2005) Prognosis of hypercalcemia in aerodigestive tract cancers Study of 136 recent cases. Oral Oncology 41:884–889
Wysolmerski JJ, Broadus AE (1994) Hypercalcemia of malignancy: the central role of parathyroid hormone related protein. Ann Rev Med 45:189–200
Skrabanek P, Mc Partlin J, Powell D (1980) Tumor hypercalcemia and “ectopic” hyperparathyroidism”. Medicine 59:262–282
Wimalawansa SJ (1994) Significance of plasma PTH-rp in patients with hypercalcemia of malignancy treated. with diphosphonate. Cancer 73:2223–2230
Walls J, Ratcliffe WA, Howell A, Bundred NJ (1994) Response to intravenous biphosphonate therapy in hypercalcemic patients without bone metastases: the role of parathyroid hormone-related protein. Br J Cancer 70:169–172
Gurney H, Grill V, Martin TJ (1993) Parathyroid hormone-related protein and response to pamidronate in tumour-induced hypercalcemia. Lancet 341:1611–1613
De Wits S, Cleton FJ (1994) Hypercalcemia in patients with breast cancer: a survival study. J Cancer Res Clin Oncol 120:610–614
Truong NU, deB Edwardes MD, Papavasiliou V, Goltzman D, Kremer R (2003) Parathyroid hormone-related peptide and survival with cancer and hypercalcemia. Am J Med 115:115–121
Augustson BM, Begum G, Dunn JA et al (2005) Early mortality after diagnosis of multiple myeloma analysis of patients entered onto the United Kingdom Medical Research Council trials between 1980 and 2002 - Medical Research Council Adult Leukemia Working Party. J Clin Oncol 23:9219–9226
Ling PJ, A’Hern RP, Hardy JR (1995) Analysis of survival following treatment of tumour-induced hypercalcemia with intravenous pamidronate (APD). Br J Cancer 72:206–209
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Penel, N., Dewas, S., Doutrelant, P. et al. Cancer-associated hypercalcemia treated with intravenous diphosphonates: a survival and prognostic factor analysis. Support Care Cancer 16, 387–392 (2008). https://doi.org/10.1007/s00520-007-0322-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00520-007-0322-z